Eloxx Pharmaceuticals (OTCMKTS:ELOXD – Get Free Report) is expected to be issuing its results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($70.40) per share for the quarter.
Eloxx Pharmaceuticals Price Performance
ELOXD stock opened at $6.20 on Monday. Eloxx Pharmaceuticals has a one year low of $0.00 and a one year high of $10.00. The firm has a 50-day simple moving average of $5.97 and a two-hundred day simple moving average of $2.55.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc (NASDAQ: ELOX) is a clinical‐stage biopharmaceutical company focused on developing precision medicines for rare genetic diseases caused by nonsense mutations. Its lead candidate, ELX-02, is a novel small molecule designed to enable ribosomal read-through of premature stop codons and restore production of full-length, functional proteins. The company’s initial therapeutic targets include cystic fibrosis and cystinosis, with ELX-02 advancing through Phase 2 clinical studies in cystic fibrosis and Phase 1/2 trials in cystinosis.
In addition to ELX-02, Eloxx is advancing second-generation read-through compounds in its discovery pipeline to broaden treatment opportunities for patients with other nonsense mutation-driven disorders.
Further Reading
- Five stocks we like better than Eloxx Pharmaceuticals
- 3 Humanoid Robot ETFs to Ride a Speculative Trend
- Bearish Pressure Is Building Around These 3 Stocks
- 3 Low-Volatility Plays Quietly Making a Name For Themselves
- ASML’s Dividend Growth Adds a Quiet Income Angle to Its AI Chip Story
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
